Afrigather Berlin, June 8, 2022 – Bayer AG introduced at present that BlueRock Therapeutics LP (BlueRock), a medical stage biopharmaceutical firm and wholly-owned subsidiary of Bayer AG, has established a brand new website for cell remedy innovation on Bayer’s campus in Berlin, Germany. This transfer comes as a part of the corporate’s centered progress technique. Whereas working independently, the workforce at BlueRock will profit from the experience of varied groups at Bayer to allow the growth and acceleration of the corporate’s medical trials to Europe. BlueRock not too long ago closed enrollment for a Section I medical trial for BRT-DA01, its novel cell remedy for treating Parkinson’s illness, and intends to provoke a worldwide non-interventional examine for Parkinson’s sufferers within the second half of 2022.
“In the present day’s announcement is a big step ahead in advancing our management in cell therapies globally. Establishing a presence for BlueRock in Europe provides the chance to strengthen our collaboration, with the last word objective to ship cell therapies with transformational potential,” stated Stefan Oelrich, Member of the Board of Administration, Bayer AG and President of Bayer’s Prescribed drugs Division. “We stay up for seeing BlueRock thrive and speed up the expansion of the corporate. Collectively we’ll translate pioneering science into tangible therapies for sufferers.”
A multidisciplinary BlueRock workforce can be arrange throughout 2022 to supply medical growth and operational help for Europe, together with chemistry, manufacturing and management (CMC). The workforce will develop as the corporate’s rising pipeline of progressive cell therapies for treating sufferers with neurological, immunological, cardiovascular and ophthalmic illnesses progresses. The co-location of the businesses’ groups in Berlin will allow BlueRock to leverage Bayer’s international attain and know-how in areas akin to regulatory affairs, medical growth, and commercialization. With the institution of its new website, BlueRock considerably broadens its geographical footprint, with presence within the US, Canada, and now Europe.
“We’re excited to develop our operations to Europe,” stated Seth Ettenberg, President and CEO of BlueRock Therapeutics. “The institution of a website in Europe is a vital milestone in our progress technique that can allow us to increase the attain of our advancing pipeline of novel cell therapies to sufferers globally.”
Bayer and BlueRock share a dedication to creating new therapies to deal with devastating illnesses in areas of excessive unmet medical want. For the reason that inception of BlueRock in 2016 by Versant Ventures and Bayer AG, the corporate has grown from a pre-clinical start-up to a clinical-stage firm with websites in the US, Canada and now Europe. As a foundational factor of Bayer’s cell and gene remedy technique, the growth of BlueRock’s geographical presence strengthens Bayer’s capabilities in cell therapies and as a driver of recent applied sciences worldwide.
In regards to the BRT-DA01 Section I Trial
The first goal of the PhI trial is to evaluate the protection and tolerability of BRT-DA01 transplantation at one-year post-transplant. The secondary goals of the trial are to evaluate the proof of transplanted cell survival and motor results at one- and two-years post-transplant, to judge continued security and tolerability at two years, and to evaluate feasibility of transplantation.
In the US, the trial was initiated at Weill Cornell Drugs with Dr. Harini Sarva, M.D. because the Principal Investigator (PI) and first surgical procedures being carried out by Dr. Viviane Tabar, Chair of the Division of Neurosurgery at Memorial Sloan Kettering Most cancers Middle. Extra Neurology websites have been added on the College of California, Irvine, beneath the steering of Dr. Claire Henchcliffe, M.D., D.Phil., F.A.A.N., F.A.N.A. (PI), and on the College Well being Community (UHN), beneath the steering of Dr. Lozano, O.C., M.D., Ph.D., F.R.C.S.C., F.R.S.C., F.C.A.H.S. (PI) and Dr. Alfonso Fasano, M.D., PhD., Chair in Neuromodulation and Multi-Disciplinary Care, UHN and UoT.
Extra details about the Section I trial is on the market at clinicaltrials.gov (NCT#04802733).
As a subsequent step, BlueRock Therapeutics plans to provoke a worldwide non-interventional examine within the second half of 2022.
Extra details about the non-interventional examine is on the market at clinicaltrials.gov (NCT#05363046).
About Parkinson’s Illness
Parkinson’s illness is a progressive neurodegenerative dysfunction attributable to nerve cell injury within the mind, resulting in decreased dopamine ranges. The worsening of motor and non-motor signs is attributable to the lack of dopamine-producing neurons. At analysis, it’s estimated that sufferers have already misplaced 60-80% of their dopaminergic neurons. Parkinson’s illness usually begins with a tremor in a single hand. Different signs are rigidity, cramping and slowness of motion (bradykinesia). In line with the Parkinson’s Basis, greater than 10 million individuals worldwide endure from Parkinson’s illness. BRT-DA01 is being clinically evaluated in a subset of sufferers with Parkinson’s illness, the place common drugs are not totally efficient.
About Bayer
Bayer is a worldwide enterprise with core competencies within the life science fields of well being care and vitamin. Its services and products are designed to assist individuals and the planet thrive by supporting efforts to grasp the most important challenges offered by a rising and growing older international inhabitants. Bayer is dedicated to driving sustainable growth and producing a optimistic influence with its companies. On the identical time, the Group goals to extend its incomes energy and create worth by way of innovation and progress. The Bayer model stands for belief, reliability and high quality all through the world. In fiscal 2021, the Group employed round 100,000 individuals and had gross sales of 44.1 billion euros. R&D bills earlier than particular gadgets amounted to five.3 billion euros. For extra data, go to www.bayer.com.
About BlueRock Therapeutics
BlueRock Therapeutics is a number one engineered cell remedy firm with a mission to create genuine mobile medicines to reverse devastating illnesses, with the imaginative and prescient of bettering the human situation. The Firm’s cell+gene platform harnesses the ability of cells to create new medicines for neurology, cardiology, immunology and ophthalmology indications. BlueRock Therapeutics’ cell differentiation expertise recapitulates the cell’s developmental biology to supply genuine cells, a few of that are engineered for extra therapeutic perform. Using these cell therapies to exchange broken or degenerated tissue brings the potential to revive misplaced perform. BlueRock Therapeutics was based in 2016 by Versant Ventures and Bayer AG and capitalized with one of many largest-ever Sequence A financings in biotech historical past by Bayer AG (by way of its Leaps by Bayer unit) and Versant Ventures. The corporate was totally acquired by Bayer in 2019. BlueRock Therapeutics’ tradition is outlined by the braveness to persist whatever the problem, the urgency to remodel drugs and ship hope, integrity guided by mission, and community-mindedness with the understanding that we’re all a part of one thing greater than ourselves. For extra data, go to www.bluerocktx.com.
Ahead-Trying Statements
This launch could comprise forward-looking statements based mostly on present assumptions and forecasts made by Bayer administration. Numerous recognized and unknown dangers, uncertainties and different elements might result in materials variations between the precise future outcomes, monetary scenario, growth or efficiency of the corporate and the estimates given right here. These elements embody these mentioned in Bayer’s public studies which can be found on the Bayer web site at www.bayer.com. The corporate assumes no legal responsibility in any respect to replace these forward-looking statements or to evolve them to future occasions or developments.
